Short Interest in Gamida Cell Ltd. (NASDAQ:GMDA) Grows By 9.8%

Gamida Cell Ltd. (NASDAQ:GMDAGet Free Report) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 10,960,000 shares, an increase of 9.8% from the February 29th total of 9,980,000 shares. Based on an average daily trading volume, of 3,020,000 shares, the short-interest ratio is presently 3.6 days.

Analysts Set New Price Targets

A number of equities analysts have commented on GMDA shares. JMP Securities reaffirmed a “market perform” rating on shares of Gamida Cell in a report on Monday, January 29th. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price objective on shares of Gamida Cell in a research report on Tuesday, December 5th.

View Our Latest Analysis on Gamida Cell

Institutional Trading of Gamida Cell

A number of large investors have recently modified their holdings of GMDA. Bank of America Corp DE grew its position in Gamida Cell by 539.0% in the 1st quarter. Bank of America Corp DE now owns 15,214 shares of the company’s stock worth $63,000 after purchasing an additional 12,833 shares during the last quarter. Lazard Asset Management LLC bought a new position in Gamida Cell in the 2nd quarter worth approximately $30,000. Virtu Financial LLC acquired a new stake in Gamida Cell in the 2nd quarter valued at approximately $36,000. Cubist Systematic Strategies LLC bought a new stake in Gamida Cell during the 2nd quarter valued at $42,000. Finally, Osaic Holdings Inc. raised its stake in shares of Gamida Cell by 698.7% during the second quarter. Osaic Holdings Inc. now owns 24,281 shares of the company’s stock valued at $47,000 after purchasing an additional 21,241 shares in the last quarter. Institutional investors and hedge funds own 50.34% of the company’s stock.

Gamida Cell Stock Performance

NASDAQ GMDA traded up $0.01 during trading hours on Tuesday, hitting $0.05. The company had a trading volume of 83,621,158 shares, compared to its average volume of 8,233,934. The company has a quick ratio of 2.09, a current ratio of 2.16 and a debt-to-equity ratio of 213.14. The firm has a market cap of $4.81 million, a P/E ratio of -0.06 and a beta of 0.94. Gamida Cell has a fifty-two week low of $0.03 and a fifty-two week high of $2.51. The business has a fifty day simple moving average of $0.34 and a 200-day simple moving average of $0.49.

Gamida Cell Company Profile

(Get Free Report)

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia.

See Also

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with's FREE daily email newsletter.